Literature DB >> 2368793

Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates.

W D Kaehny1, D J Tangel, A M Johnson, W J Kimberling, R W Schrier, P A Gabow.   

Abstract

PURPOSE: Patients with autosomal dominant polycystic kidney disease (ADPKD) are alleged to have more frequent or more pronounced alterations of uric acid homeostasis than are seen in most other types of chronic renal diseases. We performed this study to examine the hypothesis that individuals with ADPKD have abnormal uric acid homeostasis that is manifest before the development of renal insufficiency. PATIENTS AND METHODS: We studied 301 subjects, 163 with ADPKD and 138 relatives without ADPKD (NADPKD), by ultrasonography. The subjects were interviewed and examined. Venous blood and two 24-hour urine collections were obtained for uric acid and creatinine determinations.
RESULTS: Presence of hyperuricemia, serum uric acid levels, uric acid clearance, and fractional excretion of uric acid did not differ between ADPKD and NADPKD subjects with normal renal function (creatinine clearance greater than 80 mL/minute/1.73 m2). Clearance of uric acid decreased and fractional excretion increased in subjects with decreased renal function in both groups. Female gender enhanced renal excretion of uric acid in both groups and hypertension depressed it except in men with ADPKD, who had higher fractional excretions of uric acid than did hypertensive NADPKD men.
CONCLUSIONS: Uric acid homeostasis is preserved in individuals with ADPKD with normal renal function when compared to unaffected family members. Hyperuricemia and decreased renal excretion of uric acid develop as renal function worsens in ADPKD, similar to that in control subjects. The expected depressing effect of hypertension on renal handling of uric acid was not seen in men with ADPKD, speculatively due to an effect of atrial natriuretic factor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2368793     DOI: 10.1016/0002-9343(90)90097-w

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  The relation of anthropometric measurements and insulin resistance in patients with polycystic kidney disease.

Authors:  Bennur Esen; Emel Sağlam Gokmen; Mahmut Kaya; Burak Ozkan; Ahmet Engin Atay
Journal:  J Transl Int Med       Date:  2016-09-23

Review 2.  Lithiasis in cystic kidney disease and malformations of the urinary tract.

Authors:  G Gambaro; A Fabris; D Puliatta; A Lupo
Journal:  Urol Res       Date:  2006-01-14

3.  Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Authors:  Mattheus K Reinders; Eric N van Roon; Pieternella M Houtman; Jacobus R B J Brouwers; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

4.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

5.  Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Ke Wang; Leila R Zelnick; Yan Chen; Andrew N Hoofnagle; Terry Watnick; Stephen Seliger; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-18       Impact factor: 8.237

6.  Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.

Authors:  Miyeun Han; Hayne Cho Park; Hyunsuk Kim; Hyung Ah Jo; Hyuk Huh; Joon Young Jang; Ah-Young Kang; Seung Hyup Kim; Hae Il Cheong; Duk-Hee Kang; Jaeseok Yang; Kook-Hwan Oh; Young-Hwan Hwang; Curie Ahn
Journal:  BMC Nephrol       Date:  2014-04-16       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.